Topical Microbicides to Prevent HIV: Clinical Drug Development Challenges

被引:56
作者
Hendrix, Craig W. [1 ]
Cao, Ying Jun [1 ]
Fuchs, Edward J. [1 ]
机构
[1] Johns Hopkins Univ, Div Clin Pharmacol, Sch Med, Baltimore, MD 21218 USA
关键词
pre-exposure prophylaxis; antiretroviral drugs; adverse events; pharmacokinetics; pharmacodynamics; clinical trial simulation; HUMAN-IMMUNODEFICIENCY-VIRUS; VAGINAL GEL; IN-VIVO; LAMIVUDINE-TRIPHOSPHATE; TENOFOVIR DIPHOSPHATE; RISK-FACTORS; SELF-REPORT; TRANSMISSION; NONOXYNOL-9; INFECTION;
D O I
10.1146/annurev.pharmtox.48.113006.094906
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Microbicides, Substances applied topically to prevent sexual HIV infection, are needed to empower receptive sexual partners with effective prevention methods. Several large microbicide trials, however, failed to demonstrate efficacy, thus motivating a reevaluation of the current microbicide development paradigm, which has been largely empirically based. Microbicide use occurs in a highly complex environment involving multi-level interactions, behavioral and biochemical, among host, virus, and drug, yet many details of these interactions remain unknown. Fundamental information regarding virus and drug distribution over time in sexually receptive body compartments that is necessary to design a microbicide able to outdistance and outlast the virus is largely absent-Recent efforts have been made to establish a simple conceptual framework for obtaining the knowledge that is likely to inform a more mechanistic, model-based development paradigm. These efforts have also advanced the development of numerous methodological approaches to obtain the knowledge needed to improve microbicide development.
引用
收藏
页码:349 / 375
页数:27
相关论文
共 98 条
[1]   A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection [J].
Abner, SR ;
Guenthner, PC ;
Guarner, J ;
Hancock, KA ;
Cummins, JE ;
Fink, A ;
Gilmore, GT ;
Staley, C ;
Ward, A ;
Ali, O ;
Binderow, S ;
Cohen, S ;
Grohskopf, LA ;
Paxton, L ;
Hart, CE ;
Dezzutti, CS .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (09) :1545-1556
[2]  
ALEXANDER NJ, 1987, AM J REPROD IM MIC, V15, P47
[3]  
*ALL MICR RES, 2008, MICR PIP
[4]   Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults [J].
Anderson, Peter L. ;
Zheng, Jia-Hua ;
King, Tracy ;
Bushman, Lane R. ;
Predhomme, Julie ;
Meditz, Arnie ;
Gerber, John ;
Fletcher, Courtney V. .
AIDS, 2007, 21 (14) :1849-1854
[5]  
Aungst BJ, 2000, J PHARM SCI, V89, P429, DOI 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO
[6]  
2-J
[7]  
Bangsberg D.R., 2001, AIDS BEHAV, V5, P275, DOI [DOI 10.1023/A:1011396711486, https://doi.org/10.1023/A:1011396711486]
[8]   Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population [J].
Bangsberg, DR ;
Hecht, FM ;
Charlebois, ED ;
Zolopa, AR ;
Holodniy, M ;
Sheiner, L ;
Bamberger, JD ;
Chesney, MA ;
Moss, A .
AIDS, 2000, 14 (04) :357-366
[9]   Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults [J].
Barditch-Crovo, P ;
Deeks, SG ;
Collier, A ;
Safrin, S ;
Coakley, DF ;
Miller, M ;
Kearney, BP ;
Coleman, RL ;
Lamy, PD ;
Kahn, JO ;
McGowan, I ;
Lietman, PS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2733-2739
[10]   In vivo assessment of NuvaRing® placement [J].
Barnhart, KT ;
Timbers, K ;
Pretorius, ES ;
Lin, K ;
Shaunik, A .
CONTRACEPTION, 2005, 72 (03) :196-199